Mark Posner, MD
Urology · Baton Rouge, LANPI 1255391660
Payments from drug & device makers
Across 301 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$780
- Antares Pharma, Inc.$358
- Teleflex LLC$342
- Pfizer$322
- Boston Scientific$301
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,62399%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $1,300 |
| Astellas Pharma US Inc | 49 | $780 |
| Antares Pharma, Inc. | 16 | $358 |
| Teleflex LLC | 5 | $342 |
| Pfizer | 16 | $322 |
| Boston Scientific | 15 | $301 |
| Johnson & Johnson(2 entities) | 19 | $290 |
| Blue Earth Diagnostics | 7 | $236 |
| Sumitomo Pharma America, Inc. | 10 | $228 |
| Urogen Pharma, Inc. | 7 | $170 |
| Dendreon Pharmaceuticals LLC | 6 | $131 |
| Bayer | 8 | $114 |
| Axonics, Inc. | 3 | $108 |
| Accord Healthcare, Inc. | 5 | $83 |
| AstraZeneca | 5 | $82 |
| Ferring Pharmaceuticals Inc. | 4 | $72 |
| Progenics Pharmaceuticals, Inc. | 3 | $69 |
| Endo Pharmaceuticals Inc. | 4 | $64 |
| Coloplast | 3 | $60 |
| Tolmar Pharmaceuticals, Inc. | 4 | $58 |
| Myovant Sciences Inc. | 2 | $46 |
| Merck | 2 | $44 |
| Travere Therapeutics, Inc. | 3 | $43 |
| Laborie Medical Technologies Corp. | 2 | $41 |
| Mission Pharmacal Company | 3 | $37 |
| Neotract Inc. | 2 | $30 |
| Clarus Therapeutics Inc. | 3 | $28 |
| Rochester Medical Corporation | 2 | $28 |
| Procept Biorobotics Corporation | 1 | $26 |
| Photocure Inc | 2 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| Urovant Sciences Inc | 1 | $22 |
| Agiliti Surgical, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Olympus America Inc. | 1 | $16 |
| Kerecis Limited | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Halozyme Inc | 1 | $13 |
| Ambu Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,663 in reported general payments places this provider in the 65th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 232 | $183,810 |
| GemtesaVibegron | 136 | $103,309 |
| Tamsulosin Hcl | 1,724 | $25,820 |
| Estradiol | 163 | $13,178 |
| Finasteride | 828 | $11,081 |
| Testosterone | 71 | $9,888 |
| Solifenacin Succinate | 176 | $6,500 |
| Testosterone Cypionate | 286 | $6,220 |
| Oxybutynin Chloride ErOxybutynin Chloride | 319 | $5,595 |
| Bethanechol Chloride | 66 | $5,393 |
| Potassium Citrate ErPotassium Citrate | 69 | $4,552 |
| NitrofurantoinNitrofurantoin Macrocrystal | 115 | $3,947 |
| Imipramine Hcl | 165 | $3,641 |
| Methenamine Hippurate | 45 | $3,513 |
| Cefdinir | 174 | $2,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $780 | $183,810232 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $228 | $103,309136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 199 urology providers in Louisiana.
Other urology in Baton Rouge
- Jason BridgesBaton Rouge$15K
- James MorrisBaton Rouge$8K
- Stephen VickBaton Rouge$7K
- Ralph HendersonShreveport$4M
- Kevin ClineShreveport$1.3M
- Nathan FischmanNew Orleans$1.3M
- Ashley BakerShreveport$705K
- Colin GoudelockeNew Orleans$615K
- Stephen BardotNew Orleans$572K
- Gerard HenryBossier City$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.